Why in news?
The Lasker Foundation announced its 2026 Basic Medical Research Award on 9 September. Emmanuel Mignot and Masashi Yanagisawa share the honour for discoveries involving orexin and narcolepsy. Their separate studies connected a brain signalling system with stable wakefulness. This work also opened a direct route towards newer treatments.
What is narcolepsy?
Narcolepsy is a lifelong neurological sleep disorder. The brain struggles to control the boundary between sleep and wakefulness. A person may feel overwhelming daytime sleepiness despite spending enough time in bed. Sudden sleep episodes can interrupt study, work, travel or conversation.
Night-time sleep may also become broken and unrestful. Some people experience vivid dream-like images while falling asleep or waking. Sleep paralysis can briefly prevent movement at those times. These experiences arise from disturbed sleep regulation, not weak will or laziness.
Doctors distinguish two main forms. Type 1 includes cataplexy or very low orexin levels. Cataplexy causes sudden muscle weakness, often after laughter or another strong emotion. Type 2 lacks cataplexy, and its underlying biology remains less clearly understood.
Why orexin matters
Orexin is a small signalling peptide produced by specialised neurons in the hypothalamus. This brain region helps regulate sleep, appetite and several body functions. Orexin signals through two receptors on other cells. The signalling network helps maintain wakefulness and control muscle tone.
Yanagisawa’s group identified orexin and its receptors during the late 1990s. Mice lacking orexin later showed fragmented waking and sudden loss of muscle tone. Those features closely resembled narcolepsy with cataplexy. The result revealed an unexpected role for the newly found molecule.
Mignot approached the problem through families of dogs with inherited narcolepsy. His group traced that form to a mutation affecting the second orexin receptor. The canine result and the mouse experiments converged in 1999. Two different research paths had identified the same signalling system.
From animal findings to human disease
Most human cases do not follow the simple mutation seen in those dogs. Researchers instead found very low orexin in many people with Type 1 narcolepsy. Later evidence linked this shortage to selective loss of orexin-producing neurons. An immune attack is the leading explanation for that loss.
Genes can influence susceptibility without deciding a person’s future. Environmental triggers may also matter, but their effects are complex. Therefore, a genetic marker alone cannot diagnose narcolepsy. The discoveries explain an important disease mechanism without reducing every case to one cause.
The award recognises basic research that gradually changed clinical understanding. It did not follow one isolated experiment or an immediate cure. Years of genetics, animal research and patient studies built the connection. This history shows why long-term investigation remains essential in medical science.
Diagnosis and everyday management
Diagnosis begins with a detailed sleep history and an examination. Doctors may request overnight monitoring to assess sleep and exclude other conditions. A daytime multiple sleep latency test measures how quickly sleep begins. Cerebrospinal fluid orexin testing is useful in selected cases.
Symptoms can overlap with sleep deprivation, medicines, depression or other sleep disorders. This makes professional assessment important. Delayed diagnosis can affect education, employment and emotional health. Accurate recognition also helps families understand that the symptoms have a biological basis.
Management usually combines regular sleep schedules, planned naps and prescribed medicines. Choices depend upon symptoms, occupation, age and other health conditions. Safety planning is crucial around driving, heights and machinery. Schools and workplaces can support predictable breaks and reasonable adjustments.
A direct treatment pathway
Earlier medicines mainly reduced particular symptoms through indirect pathways. Orexin research suggested a different approach: replacing the missing signal. In August 2026, the United States approved oveporexton for adults with Type 1 narcolepsy. It directly activates an orexin receptor in the brain.
The approval is important, but it does not remove every clinical question. Long-term effectiveness and safety still require continuing observation. Access, cost and suitability will vary among patients and countries. It also does not establish the same approach for Type 2 narcolepsy.
Wider scientific significance
The orexin pathway improved understanding of normal waking, not only one disorder. Medicines that block this system are used differently to promote sleep. Medicines that activate it may support wakefulness. The same biological pathway can therefore guide opposite treatments when used with precision.
Basic discoveries often reach patients through several careful stages. Researchers must confirm mechanisms, design suitable molecules and test them in controlled trials. Regulators then assess benefits and risks for a defined group. The Lasker recognition highlights that complete chain of scientific translation.
Conclusion
The 2026 award honours a clear explanation for one major form of narcolepsy. Separate animal and human studies revealed orexin’s central role in wakefulness. That insight changed diagnosis, reduced stigma and guided direct treatment development. Continued research must now improve access and address the less understood forms.